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Abstract: The rollout of antiretroviral therapy (ART) significantly reduced human immuno-
deficiency virus (HIV)-related morbidity and mortality, but good clinical outcomes depend on 
access and adherence to treatment. In resource-limited settings, where over 90% of the world’s 
HIV-infected population resides, data on barriers to treatment are emerging that contribute to 
low rates of uptake in HIV testing, linkage to and retention in HIV care systems, and subop-
timal adherence rates to therapy. A review of the literature reveals limited evidence to inform 
strategies to improve access and adherence with the majority of studies from sub-Saharan 
Africa. Data from observational studies and randomized controlled trials support home-based, 
mobile and antenatal care HIV testing, task-shifting from doctor-based to nurse-based and 
lower level provider care, and adherence support through education, counseling and mobile 
phone messaging services. Strategies with more limited evidence include targeted HIV testing 
for couples and family members of ART patients, decentralization of HIV care, including 
through home- and community-based ART programs, and adherence promotion through peer 
health workers, treatment supporters, and directly observed therapy. There is little evidence 
for improving access and adherence among vulnerable groups such as women, children and 
adolescents, and other high-risk populations and for addressing major barriers. Overall, studies 
are few in number and suffer from methodological issues. Recommendations for further research 
include health information technology, social-level factors like HIV stigma, and new research 
directions in cost-effectiveness, operations, and implementation. Findings from this review 
make a compelling case for more data to guide strategies to improve access and adherence to 
treatment in resource-limited settings.
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Introduction
In 2010, the World Health Organization (WHO) estimated there were 34 million people 
living with the human immunodeficiency virus (HIV).1 The emergence of antiretrovi-
ral therapy (ART) transformed HIV from a terminal illness to a chronic disease and 
resulted in significant decreases in HIV-related morbidity and mortality;2,3 however, 
good clinical outcomes depend on access and adherence to treatment. In low- and 
middle-income countries (LMIC), home to over 90% of the HIV-infected population, 
access to ART has dramatically expanded in the last decade, yet it is estimated that only 
47% of adults and 23% of children who are eligible are accessing treatment.1 Recent 
studies suggest adults and children in resource-limited settings maintain or achieve 
better rates of adherence compared to those in resource-rich settings,4–6 but suboptimal 
adherence remains a threat for opportunistic infections,7 HIV disease progression,8–10 
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and viral resistance to ART.11–13 Evidence-based strategies 
to improve access and adherence in LMIC are critically 
needed. This paper reviews the current scientific literature 
on strategies to improve access and adherence to ART in 
LMIC. Important gaps in the literature are highlighted and 
future directions for research are proposed.
Access to ART requires successful passage through vari-
ous stages of care, including diagnosis, linkage, disease-stage 
monitoring, and finally initiation of treatment. Following 
treatment initiation, good clinical outcomes require retention 
in care and high rates of adherence to therapy.14 A number of 
quantitative and qualitative studies reveal a myriad of barriers 
at all stages of access and adherence. While some barriers 
exist across settings, others act more frequently in resource-
limited settings. Reviews of barriers to access and adherence 
often conceptualize and organize barriers according to levels 
of action15–17 consistent with a social–ecological framework 
Table 1 Barriers to access and adherence to antiretroviral 
therapy in low- and middle-income countries
Level of action Barriers
Intrapersonal Knowledge of serostatus and treatment options200–204,**
Difficulty understanding/managing 
treatment,108,116,117,120,205–207,** complicated 
regimens,116,207–213 ART side effects117,208–210,212–218
Simply forgetting to come to clinic or take 
medicines,205,207,208,213–215,219 falling asleep210,214,219
Emotional distress (eg, depression),108,214,217,220 
substance addiction205,213,221,222
Perceptions of health,206,213,214,223,224 
treatment,205,217,225,226 and alternative/traditional 
medicines227–229
Available financial resources,230,231,* food insecurity232–234
Interpersonal/ 
social
Lack of family or social support,180,235,236 dependency 
on partners for financial resources201,237,* or 
permission for treatment106,*
Household conflict,108,116,216,** Low parental 
education level117,**
Fear of violence and/or abandonment202,238,*
Lack of disclosure of own* or child’s 
status108,120,207,211–214,216,217,220,239,240,**
Negative perception of providers206,241 and poor 
patient–provider communication242,243
Lack of community involvement in ART programs16,201
Stigma and discrimination108,207,216,220,239,*
System Costs of care and treatment,205,208,213,215,244,245 distance 
to clinic205,212,213,219,246–251
Lack of integration/coordination with other health 
services252,253
Drug shortages and stock-outs218,254,255
Long waiting times at clinics229,234,256
Inadequate laboratory infrastructure/resources257
Confidentiality of services258
Notes: *Significant barrier for women; **significant barrier for children and 
adolescents.
discussed elsewhere.18,19 Table 1 summarizes commonly 
cited barriers to access and adherence in LMIC at the levels 
of intrapersonal, interpersonal/social, and system. Barriers 
more common to those living in resource-limited settings 
may include lack of knowledge of HIV status and treatment 
options, fear of stigma and discrimination, and system-level 
barriers, sometimes referred to as structural barriers,20 that 
constrain individual and community-level efficacy to access 
and adhere to treatment through poor health care infrastruc-
ture and resources. Factors such as entrenched poverty and 
inequality operate at all levels and may especially affect 
treatment opportunities for women and children. Improving 
access and adherence to ART will require interventions that 
address barriers at each level of action while also considering 
how these barriers operate at the multiple stages of treatment, 
across different contexts, and among diverse populations.
Evidence-based strategies
A review of the literature reveals limited empirical data 
to guide strategies to improve access and adherence to 
ART (Table 2). Few randomized, controlled trials (RCTs), 
widely considered the gold standard in scientific rigor and 
methodology,21,22 evaluate interventions in LMIC and strate-
gies often rely on small case and observational studies. The 
most compelling data from well-designed observational stud-
ies and RCTs conducted in LMIC are reviewed here accord-
ing to three stages of treatment: HIV testing and diagnosis; 
linkage to and retention in care; and adherence to ART.
HIV testing and diagnosis
As availability of ART in resource-limited settings expands, 
voluntary counseling and testing (VCT) services act as critical 
gateways to testing, early diagnosis and treatment.23 Despite 
massive scale-ups in national HIV testing programs,24,25 
studies suggest that up to 80% of HIV-infected adults do not 
know their status in some sub-Saharan African settings,26,27 
although rates of testing vary substantially by country. 
A national survey in Lesotho found that the percentage of 
women who had been tested for HIV in the past 12 months 
had increased from 6.3% in 2004 to 42% in 2009, while a 
similar national survey in the Congo only showed rates of 
testing increasing from 3.2% in 2004 to 6.5% in 2009.1
Low uptake in testing and barriers to accessing traditional, 
client-initiated VCT services have led to new approaches in 
HIV testing, including provider-initiated, home-based and 
mobile or community testing.28 Routine “opt-out” testing by 
providers, which is now recommended by the WHO as part 
of standard medical care in certain settings,29 is reported to 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
Scanlon and Vreeman
HIV/AIDS - Research and Palliative Care 2013:5
increase early diagnosis and access to treatment,30 especially 
within antenatal care settings.31 A number of observational 
studies show promising early results in increased testing 
uptake with home-based32–34 and mobile24,35 services. A large 
cohort study in rural Uganda found that 1 year after offering 
home-based testing services, receipt of HIV tests increased 
more than 5 times compared to previous clinic-based test-
ing.36 Studies assessing the cost-effectiveness and feasibil-
ity of home- and mobile-based testing in resource-limited 
settings have begun to emerge,37–39 but more research is 
needed.
There are few RCTs evaluating interventions to increase 
uptake of HIV testing in LMIC. An RCT investigating 
inpatient testing found that patients in an urban hospital in 
Uganda were significantly more likely to receive testing if it 
was offered during their hospital stay (intervention = 98.8%) 
compared to patients who were offered referral cards and 
travel reimbursement for testing one week after discharge 
(control = 68.7%).40 A randomized population-based study 
in Zambia found that individuals in the intervention group 
who were offered VCT at a location of their choice (84% 
chose home-based VCT) were 4.7 times more likely to 
be tested than individuals in the control who were offered 
VCT at the local health clinic.41 In the largest RCT to date, 
Sweat et al reported on Project Accept, a community-based 
intervention among communities in Tanzania, Thailand and 
Zimbabwe.42 Intervention components included community 
mobilization through HIV working groups and outreach 
coordinators, mobile VCT in community centers and other 
public places, and post-test support services.43 A mean differ-
ence of 40.2% (95% confidence interval [CI]: 15.8–64.7) was 
reported in the proportion of patients receiving HIV testing 
in intervention versus control communities, plus interven-
tion communities had more first-time testers compared to 
controls (Tanzania, 37% vs 9%; Thailand, 69% vs 23%; Zim-
babwe, 51% vs 5%).42 RCTs investigating on-site testing at 
occupational health clinics,44 and home-based testing offered 
to family members of ART patients45 also found significantly 
increased testing rates compared with controls. RCTs using 
antenatal care settings to encourage couples counseling and 
testing of sexual partners have revealed mixed success.46–48
Linkage to and retention  
in HIV care
The potential benefits of early HIV diagnosis through 
increased uptake in counseling and testing rely on effec-
tive linkage to and retention in HIV care systems. There is 
growing evidence that individuals testing positive are not 
Table 2 Evidence base for strategies to improve access and adherence in LMIC
Level of support Stage of care
Testing and diagnosis Linkage to and retention in care Adherence
Limited or weak  
evidence
Provider-initiated testing30,259
Targeted HIV testing:
Inpatient testing40,*
Couples’ testing46–48,*
Workplace testing44,*
Testing of family members of
ART patients45,*
Mass-media campaigns190
School-based HIV educational  
programs128,*
Referral programs (referral forms,  
transport stipends, patient navigators);57  
patient navigators58
Point-of-care CD4 testing;60–62,64  
pre-ART prophylaxis260
Free services;261 cash transfers for  
transportation to clinic;77,* food-assistance  
programs262
Home-based ART program;80,* 
community group-based ART program182
Patient-centered care (ex-child-friendly  
clinics,129 family-based care263,264)
Health information systems  
(ie, electronic medical records)162–166
Decentralization of HIV services70–72  
and integration into primary care, TB,  
antenatal services72–74,76
Adherence support through peer 
health workers92,* and treatment 
supporters94,95,*
Peer-delivered DOT–ART96–98,* 
and nurse-delivered DOT–ART99,*
Targeted DOT–ART for HIV–TB 
patients141–143 and children130
Adherence counseling with 
EDM87,*
Disclosure of HIV status to 
children133
Food-assistance programs90,91
Strongest evidence Non-standard approaches to VCT:
Home-based testing32–34,36–38,41,†
Mobile or community-based  
testing24,35,37,42,109,†
Testing in antenatal care settings111–113,†
Task-shifting to nurse-based,  
PHW care66–69,78,79,81,265,†
Adherence counseling/
education85,86,266,†
Mobile phone SMS100–102,267,268,†
Notes: *Evidence from RCTs; †evidence from RCTs and observational studies.
Abbreviations: DOT–ART, directly observed antiretroviral therapy; HIV, human immunodeficiency virus; PHW, peer health worker; SMS, short message services; 
RCT, randomized controlled trial; VCT, voluntary counseling and testing; TB, tuberculosis.
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effectively linked to HIV care programs, leading to late 
presentation for treatment and increased risks of HIV-related 
morbidity and mortality.49–51 Recent studies suggest between 
30%–62% of individuals who test positive are linked to care 
in resource-limited settings.40,52–54 Data on retention in care is 
also concerning. A review of data from 15 large-scale HIV 
treatment programs in LMIC revealed an average of 21% 
of patients were lost to follow-up by 6 months and 4% were 
lost after receiving their first ART prescription.55 In South 
Africa, home to over 17% of the world’s HIV-infected popu-
lation, losses to follow-up have actually been increasing in 
recent years,56 a possible indicator of the burden placed on 
under-resourced health care systems as more individuals 
access treatment.
Strategies to improve linkages and retention are emerging, 
although many studies suffer from weak study design and small 
sample sizes. In a case study in rural Tanzania, introduction 
of simple referral forms, along with transportation stipends 
and community navigators, showed success in increasing 
and monitoring linkages to care.57 A cross-sectional study in 
Kenya supported mobile testing alongside patient navigators 
to improve linkage.58 Utilization of point-of-care CD4 count 
technology is being evaluated to enhance CD4 monitoring, 
improve referral services for timely initiation of ART and 
decrease loss to follow-up.59–63 In a cohort study in Mozam-
bique, implementation of point-of-care CD4 testing at primary 
health centers resulted in a decrease in loss to follow-up before 
completion of CD4 staging (from 57% to 21%), decrease in 
loss to follow-up before treatment initiation (from 64% to 33%) 
and an increase in enrolled patients initiating ART (from 12% 
to 22%).64 In accordance with global guidelines for HIV care in 
LMIC,65 HIV care systems are implementing various system-
level changes to improve linkage and retention.  Observational 
studies generally report positive impacts on linkage, reten-
tion and overall treatment outcomes with task-shifting from 
doctor-based to nurse-based care,66–69 decentralization of HIV 
services from higher level facilities to satellite clinics,70–72 
and integration of HIV care into tuberculosis (TB), antenatal 
and other primary care services.73,74 Other studies highlight 
the need for careful implementation in the transition of these 
services to ensure personnel are trained properly and resources 
are available.75,76
Evidence from RCTs evaluating linkage to and retention 
in HIV care is limited. A randomized trial in Uganda found 
that inpatient HIV testing resulted in only 56% of patients 
enrolling in HIV care, actually lower than the control group 
that was offered referral to outpatient testing.40 An RCT 
in rural Uganda found that cash transfers (approximately 
US$5–$8 per patient per month) for transportation to clinic 
appointments significantly decreased loss to follow-up 
(P = 0.04) among the intervention group, although sample 
size was small.77 Supporting the efficacy of task-shifting to 
nurse-managed care, a randomized non-inferiority trial in 
Uganda found that a nurse–peer model achieved comparable 
rates of adherence, viral load, and CD4 counts compared 
to standard clinician-based care.78 An RCT in South Africa 
found nurse-based care to be equivalent to doctor-managed 
care in treatment failure and retention in care, with hazard 
ratios of 1.09 (95% CI: 0.89–1.33) and 1.13 (95% CI: 
0.81–1.59), respectively.79 A cluster-randomized trial found 
that home-based HIV care through trained lay workers who 
supported drug delivery and monitored clinical status and 
adherence in patients was as effective as standard clinic-
based care in Uganda in achieving equivalence in its pri-
mary endpoint, viral failure (relative risk [RR] 1.04, 95% 
CI: 0.78–1.40), and in secondary endpoints, mortality (RR 
0.95, 95% CI: 0.71–1.28) and proportion of patients who 
reported 100% adherence (94% in home-based interven-
tion group versus 91% in standard care group).80 While the 
study reported no significant difference in loss to follow-up, 
home-based ART reduced overall HIV care costs incurred by 
patients by 50% in the first year and by 66% in subsequent 
years compared to clinic-based care. An RCT in Kenya found 
that an intervention using trained HIV-infected individuals 
as community care coordinators delivering monthly home 
assessments with clinic visits every 3 months resulted in 
similar clinical outcomes, including viral load, CD4 count 
and risk of opportunistic infections, compared to a control 
group with monthly clinic visits.81
Adherence to ART
A recent meta-analysis of adherence rates found 77% of 
adults achieved adequate adherence in sub-Saharan Africa 
compared to 55% in North America6 but rates vary signifi-
cantly by setting. The literature on adherence interventions is 
relatively broad. Major reviews of adherence interventions, 
conducted mostly in resource-rich settings, reveal that the 
most effective are typically patient-based, behavioral inter-
ventions designed to build patient knowledge and efficacy 
through practical medication management skills.82–84 While 
the evidence base from resource-limited settings is much 
more limited, it is still significantly wider than for testing, 
linkage, and retention interventions and provides several 
RCTs for evaluation.
A number of patient-based counseling and education 
interventions have been evaluated in LMIC, and some show 
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positive impacts on adherence.85,86 Individual adherence 
counseling at ART initiation reduced the risk of poor adher-
ence (P = 0.055) and viral failure (P = 0.01) at 18 months 
follow-up compared to controls in an RCT in Kenya, although 
only reduced risk of viral failure was statistically significant.86 
A small RCT in China found that using feedback from 
electronic dose monitoring (EDM) during counseling led 
to significant increases in mean adherence rates (P = 0.003) 
but not mean CD4 counts (P = 0.07) at 12-month follow-
up compared to controls who received counseling only.87 
Busari et al investigated the effect of a structured teaching 
method compared to standard clinic care among 620 ART 
patients in Nigeria.85 Intervention group members received 
education in 10 modules including benefits of treatment, 
adverse drug effects, self-efficacy, and social support. At 
8 months follow-up, the intervention group achieved signifi-
cantly higher rates of adherence (P , 0.001), CD4 counts 
(P , 0.001), decreased frequency of opportunistic infections 
(P = 0.002), and lower mortality (P = 0.008). Two  Brazilian 
RCTs investigating interventions delivered by social workers 
showed no effectiveness in improving adherence or biological 
markers.88,89 One study used social workers to deliver motiva-
tional interviews and counseling through home visits89 while 
the other study compared the effect of small educational 
workshops versus group video sessions.88 Supplementing 
counseling and education with material support to address 
poverty-related barriers needs further investigation. Cohort 
studies in Zambia90 and Nigeria91 support the use of food 
assistance for improving adherence among food-insecure 
patients.
Several RCTs have investigated the use of peer health 
workers, treatment supporters and directly observed therapy 
(DOT–ART), with mixed results. An RCT in Uganda using 
peer health workers to deliver clinic- and biweekly home-
based adherence counseling and social support did not find 
significant improvements in adherence over controls, but did 
show significant decreases in the risk of viral failure after 
96 weeks (RR 0.50, 95% CI: 0.44–1.49) until end of follow 
up at 192 weeks (RR 0.07, 95% CI: 0.006–0.71).92 A mixed-
methods evaluation of the intervention found that the use of 
peer health workers improved access to care, care delivery, 
and patient-provider communication.93 In another RCT in 
Uganda, use of a patient-nominated treatment supporter, a 
family member, friend, or neighbor educated on HIV and 
who agreed to attend counseling and clinic sessions with 
the patient, did not significantly increase adherence or clinic 
attendance against a standard adherence support program.94 
A study in Tanzania evaluated the impact of a treatment 
 supporter alongside standard adherence counseling and found 
no significant differences in adherence or mean CD4 counts 
compared to controls.95 A clinic-based, once-daily DOT–ART 
intervention delivered by trained peers in Mozambique found 
mean adherence rates and CD4 counts at 6 and 12 months 
follow up did not increase significantly compared to controls 
although achieving .90% adherence was significantly more 
likely for the intervention arm at 6 months (odds ratio [OR] 
2.0, 95% CI: 0.93–4.5).96 RCTs in Nigeria97 and South Africa98 
using patient-nominated DOT–ART treatment supporters 
and one in Kenya99 using nurse-based DOT–ART revealed 
initial improvements in adherence, but failed to demonstrate 
significant increases in adherence, CD4 counts, and viral 
suppression at study endpoints.
While limited in number, studies assessing interven-
tions using mobile phones have shown positive results. 
Two RCTs in Kenya investigated the use of mobile phone 
short message service (SMS) in improving adherence.100,101 
Pop-Eleches et al found that an intervention group receiv-
ing weekly SMS reminders to take ART were significantly 
more likely to achieve .90% adherence rates (P = 0.03) and 
less likely to experience treatment interruptions (P = 0.03) 
at 48 weeks’ follow-up compared to controls.101 Lester et al 
found significant improvements in adherence (P = 0.006) 
and viral suppression (P = 0.04) among an intervention 
group that received weekly interactive SMS (inquiring about 
health and well-being), with follow-up calls for nonrespon-
dents after 48 hours.100 Another RCT in Pakistan found that 
weekly phone reminders significantly improved adherence 
and decreased viral load, although sample size and length of 
follow-up were significantly less than the studies in Kenya.102 
In an RCT in Uganda discussed previously investigating 
the impact of peer health workers,92 a substudy evaluated a 
mobile phone intervention whereby health workers called and 
text messaged higher-level providers with patient-specific 
clinical information and adherence data.103 While the inter-
vention did not find significant improvements in adherence, 
biological markers or loss to follow-up in patients random-
ized to health workers in the intervention arm, a mixed-
methods evaluation revealed mobile phones improved care 
delivery and was widely believed by patients, clinic staff, 
and peer health workers to improve clinical care. Two RCTs 
investigating the impact of SMS on adherence to ART are 
ongoing in Cameroon104 and India.105
Special populations
There are a number of populations that face higher bur-
dens of HIV, worse clinical outcomes and additional and/
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or unique barriers in accessing and adhering to ART. These 
populations require particular consideration, especially in 
LMIC where they may be further marginalized and isolated 
from HIV care.
Women
In LMIC in 2010, women represented 51% of those still 
requiring treatment and 58% of those currently on ART.1 It 
is estimated that coverage – the percentage of individuals 
needing treatment who are receiving it – among women 
is higher than men, especially in Asia and sub-Saharan 
Africa, while coverage rates for women in Latin America 
are slightly lower. Young women face an especially high 
burden of HIV in sub-Saharan Africa, where women make 
up 71% of HIV-positive young adults aged 15–24 years 
old.1 Preventing mother-to-child transmission, which is the 
route of infection in 90% of HIV-positive children in LMIC, 
hinges on expanding access and adherence to ART among 
pregnant mothers. In 2010, only 35% of pregnant women 
in LMIC received an HIV test and 48% of HIV-infected 
pregnant women accessed ART regimens as recommended 
by the WHO to prevent vertical transmission.1 Women in 
many settings face additional barriers to access and adher-
ence to treatment. Qualitative studies suggest important 
sex-based barriers may dissuade women from accessing 
and adhering to HIV treatment, including requiring a 
male partner’s permission to seek testing and treatment 
services.106 Women in some settings fear disclosing their 
HIV status to their partner because of potential negative 
consequences of emotional or physical abuse107 or forcible 
displacement from their homes.108 In many LMIC, women 
are particularly vulnerable to poverty and socioeconomic 
inequalities that create additional barriers to access and 
adherence such as low levels of education, social status, 
and financial resources.
Few studies in LMIC evaluate interventions aimed spe-
cifically at improving women’s access and adherence to HIV 
care. Qualitative studies of home-based and mobile VCT 
services reveal that these approaches may be more available 
to women as they do not require travel to clinic or permission 
and/or money from partners.109,110 Provider-initiated coun-
seling and testing for women in antenatal care settings has 
been shown to be well-accepted and to significantly increase 
testing uptake and participation in prevention of mother-to-
child transmission care.111,112 A cluster RCT in Zambia found 
that counseling and testing services in hospital labor wards 
increased the number of women on ART during birth and 
improved adherence.113
Children and adolescents
In 2010, there were an estimated 3.4 million children under 
15 years living with HIV. Adolescents represent one of 
the fastest-growing HIV-infected populations in the world. 
Young people aged 15–24 years now make up 41% of new 
HIV infections in persons older than 15 years.114 Children 
and adolescents in resource-limited settings bear an alarming 
burden of the HIV epidemic, but are less likely to achieve 
adequate adherence and to have good clinical outcomes com-
pared to their adult counterparts.115 Children and adolescents 
face complex barriers to access and adherence as the extent 
of their autonomy varies over the developmental course and 
they frequently rely on caregivers for treatment. Caregiver 
beliefs,116 education,117 and stress,118 as well as type of fam-
ily structure,117 all influence pediatric access and adherence 
to ART. Vulnerable children, such as orphans, often face 
additional barriers to care.119 Disclosure of the child’s HIV 
status, essential for long-term disease management, is asso-
ciated with improved adherence,120 emotional health,121 and 
reduced conflict with caregivers,122 but disclosure rates vary 
and are generally low in resource-limited settings (Vreeman 
et al, unpublished data, 2012). Children, as adults, report 
experiencing various levels of HIV-related discrimination.123 
Furthermore, issues that arise as children and adolescents 
transition from pediatric to adult care settings in LMIC have 
not been investigated sufficiently.124
Evidence for strategies to improve access and adher-
ence to ART for children and adolescents is lacking. Two 
major reviews of interventions to improve adherence among 
children revealed limited support for home-based nursing 
care, peer support, and education sessions for caregivers 
and children to improve adherence; however, many studies 
suffered from weak methodologies, small sample sizes, and 
few were conducted in LMIC.125,126 Other reviews suggest 
that, along with child and caregiver-level interventions, 
improved ART regimens for children (palatability, pill bur-
den/size) and relationships with providers can lead to better 
adherence to ART in children.127 Fewer studies evaluate 
access to treatment in children. An RCT in Swaziland showed 
the effectiveness of a school-based educational intervention 
in increasing HIV testing rates among students.128 A compre-
hensive care program in Kenya offering individual and group 
psychosocial support and treatment literacy for children and 
caregivers within a tailored, child-centered care model found 
improved clinical outcomes; however, individual components 
of the program could not be evaluated.129 Evaluation of a 
clinic-based DOT–ART program in Cambodia showed sig-
nificantly improved CD4 counts (P , 0.001) after 18 months 
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for orphaned children.130 Few studies examine the impact of 
disclosure on emotional health and adherence,131 but evalu-
ation of one clinic-based disclosure program in Puerto Rico 
found improved rates of adherence after implementation132 
and disclosure was linked to higher rates of adherence among 
children in Zambia.133
Other high-risk populations
Additional high-risk populations for HIV that need to be 
considered for targeted interventions include: individuals 
with comorbidities such as HIV–TB, substance abusers and 
individuals with mental disorders, men who have sex with 
men (MSM), sex workers, and prisoners. In 2010, there were 
8 million new cases of TB worldwide with 13% of newly 
infected individuals also being HIV-positive.134 The vast 
majority of individuals living with HIV–TB, an estimated 
82%, reside in sub-Saharan Africa.134 The prevalence of 
substance abuse and psychiatric disorders is high among 
HIV-infected individuals, with many suffering from all 
three comorbidities.135 While substance abuse and mental 
disorders are associated with poorer adherence and treatment 
outcomes in resource-rich settings,136 less is known about 
prevalence and impact in LMIC.137 A recent meta-analysis of 
studies from LMIC found MSM were almost 20 times more 
likely to be infected with HIV than the general population, 
highlighting the risks faced by this population.138 In LMIC, 
prevalence of HIV among female sex workers was estimated 
at 11.8% (95% CI: 11.6–12.0) while among the 26 countries 
with the highest HIV burden, the overall prevalence jumped 
to 30.7% (95% CI: 30.2–31.3).139 Finally, prisoners represent 
another high-risk population for HIV, but there is little data 
on HIV prevalence and treatment in LMIC. Small surveys in 
sub-Saharan Africa suggest high rates of HIV among prison 
populations, as high as 40% in a sample in South Africa.140
These populations face significant and, in some cases, 
unique barriers to HIV treatment, for example, criminaliza-
tion in the case of homosexuality and lack of control over 
treatment for prisoners. Research to improve access and 
adherence among these populations is virtually nonexistent 
in LMIC. Interventions that fail to show effectiveness in 
general populations may prove efficacious among targeted 
populations. While the evidence from RCTs for DOT–ART 
is not convincing among the general population, targeted 
DOT–ART, such as for HIV–TB patients, may be more 
effective and has demonstrated feasibility and efficacy in 
small observational studies in resource-limited settings.141–143 
Evidence from RCTs in resource-rich settings supports the 
use of DOT–ART for individuals with substance abuse 
disorders144–146 and prisoners.147 Depression, one of the most 
common mental disorders worldwide,148 has been shown to be 
associated with nonadherence to ART and poor  engagement 
in care in all settings.149 Evidence from resource-rich settings 
suggests improved adherence and clinical outcomes with 
combined adherence and mental health counseling.150,151 
No major studies have been conducted among MSM, sex 
workers, and prisoners, as most research and recommenda-
tions focus on prevention.152 A small observational study 
in  London found a targeted multimedia campaign aimed 
at young gay men resulted in increased uptake in clinic-
based HIV testing.153 Another small observational study in 
 Vancouver found increased adherence and viral suppression 
with a peer-delivered intervention including support groups, 
patient advocates, outreach, and onsite nursing care among a 
group of female sex workers using illicit substances, although 
there was no comparison group.154
Evaluating the evidence base
While there is increasing data on barriers to treatment, a 
review of the scientific literature reveals limited evidence 
for strategies to improve access and adherence to ART in 
resource-limited settings. Interventions broadening HIV test-
ing approaches, such as home-based, community, and mobile 
testing, show early evidence of increasing HIV testing and 
diagnosis. Observational and case studies generally support 
shifts in HIV care to improve retention through decentral-
ization and integration of services, but only task-shifting 
to nurse- and peer health worker-based care is supported 
by RCTs. A larger evidence base is found for interventions 
directed at improving adherence. Adherence counseling 
and education interventions have been effective in some 
settings, and recent evidence supports a role for mobile 
phone  technologies. RCTs to date do not provide sufficient 
evidence for using treatment supporters and DOT–ART to 
improve adherence among general populations; however, 
these strategies may be efficacious for certain populations 
such as children, HIV–TB patients, and substance abusers.
Studies assessing interventions directed at women, 
children, and adolescents and other special populations are 
scarce in LMIC. Provider-initiated inpatient testing has 
demonstrated feasibility and improved access for women 
in antenatal care settings, but few other interventions have 
been investigated adequately. This review also highlights the 
limited geographic variability among intervention studies to 
improve access and adherence, with the vast majority of the 
studies conducted in a few sub-Saharan African countries, 
including Kenya, South Africa, Uganda, and Zambia. While 
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sub-Saharan Africa represents the epicenter of the HIV 
epidemic, studies investigating access and adherence are 
needed in other resource-constrained parts of the world where 
population and system-level contextual factors necessitate 
different approaches.
There are a number of critical weaknesses in studies 
evaluated for this review. A lack of standardization in evalu-
ating linkage, retention, and adherence is an issue for both 
research and delivery of clinical care. While there are no 
common protocols to assess linkage, retention may be mea-
sured through gaps in care, clinic visits per interval of time, 
and number of missed visits.155 Further, individuals with HIV 
are a mobile population, moving through different stages of 
care, but also to different clinics and providers for care.156,157 
Systems that monitor and link patients between points of 
care are essential for improving treatment and continuity 
of care. Adherence measures vary in different settings and 
common measures include self and proxy reports, pill counts, 
pharmacy refills, EDM, virologic markers (CD4 counts, viral 
loads), and blood draws for drug concentrations. No gold 
standard for measuring adherence has been proposed,158 and 
studies often use multiple measure to improve estimates.159 
Long-term, routine monitoring of adherence is required to 
ensure optimal delivery of care, as adherence often decreases 
over time,160,161 but also to evaluate the effectiveness of 
interventions to improve adherence. Improving the methods 
that studies and care systems utilize to monitor linkage to 
and retention in care and adherence to ART will strengthen 
findings of intervention effectiveness.
Directions for future research
There are several critical gaps in the current evidence base 
that need to be addressed in future research. As HIV care 
systems transition through task shifting, decentralization, 
and integration and as more individuals need to be retained 
in treatment, monitoring of patients is critical to improving 
and expanding delivery of HIV care. Early rollout of health 
information systems, including electronic medical records, 
has been mostly positive in LMIC,162–166 but more research 
on technology-based information and surveillance systems 
and their potential to monitor and track patients throughout 
care is needed, along with how patient navigators and com-
munity outreach workers may supplement these systems. As 
HIV care systems horizontally integrate with other primary 
care services, there is an opportunity to implement various 
technologies into patient-based care that will improve not 
only HIV care, but strengthen local health care systems 
more broadly.
HIV-related stigma and discrimination remain major 
barriers to HIV treatment in LMIC, but this review found 
no major studies evaluating interventions to improve access 
and adherence through reducing stigma and discrimination 
against people living with HIV. A recent systematic review 
of interventions aimed at reducing HIV stigma evaluated 
19 studies, of which nine were conducted in LMIC; however, 
studies suffered from various methodological weaknesses and 
no studies examined the association between reduced HIV 
stigma and health outcomes such as access and adherence to 
treatment.167 Very few studies investigating interventions to 
improve access and adherence include measures of stigma as 
secondary outcomes, although this review did find two such 
studies: a cohort study in Peru using community health work-
ers delivering DOT–ART168 and an RCT in Kenya discussed 
previously assessing nurse-based DOT–ART.169 Further 
research on interventions aiming to reduce stigma, validation 
of stigma measures, and examining the association between 
intervention effects and health outcomes such as access and 
adherence are vital for addressing the significant challenges 
in HIV treatment due to stigma and discrimination. Issues 
in disclosure of HIV status, impacted by levels of perceived 
stigma, also deserve further investigation.
Social support networks have been identified in qualita-
tive studies as important facilitators of HIV treatment, includ-
ing adherence.170–172 Evidence for treatment supporters among 
qualitative and observational studies generally reveals more 
positive impacts on adherence and treatment outcomes than 
RCTs,173–178 and their findings warrant further investigation 
into the potential role for patient-nominated, family, friend 
or peer supporters in improving access and adherence. In 
sub-Saharan Africa, O’Laughlin et al suggest that treatment 
partners go beyond encouraging adherence to restoring access 
to social and community resources.179 In this way, treatment 
supports are sources of social capital and are important for 
obtaining treatment-sustaining resources such as money for 
transportation or food.180 As more patients in LMIC become 
ART experienced, “expert patients” from the community can 
likely play a crucial role in interventions to increase access 
and adherence as they have intimate knowledge of barriers 
and facilitators of care.181 This review only found two studies 
using persons living with HIV to deliver interventions.81,182 
Increased involvement of this population in the design and 
implementation of interventions deserves investigation.
Simple, low-cost adherence tools such as pillboxes, 
medication planners, and calendars have not been inves-
tigated thoroughly in resource-limited settings. The use of 
pillboxes has shown efficacy in improving adherence in a US 
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cohort,183 but has not been investigated in resource-limited 
settings. There may be variations in efficacy of such tools in 
settings where keeping medications secret is highly prized or 
where health literacy is more limited. Educational treatment 
calendars showed no impact on adherence or CD4 counts in 
an RCT in Tanzania comparing adherence counseling ver-
sus adherence counseling plus calendar.95 While electronic 
dose-timing alarms show positive effects in resource-rich 
settings,184,185 an RCT in Kenya found that the use of an alarm 
device did not significantly improve adherence.86 A small 
pretest–posttest intervention study reported on the delivery 
of a culturally sensitive educational videotape to improve 
adherence to ART in South Africa and showed increased 
knowledge of ART, side effects, and overall adherence 
strategies, although there was no control group.186  Combining 
low-cost adherence tools with counseling and education 
may offer benefits to adherence, but are not well studied 
in resource-limited settings. Another low-cost strategy to 
increase uptake in testing and utilization of services is mass 
media campaigns that can educate communities, raise aware-
ness of availability of services,187 and may address issues 
of stigma.188 A Cochrane systematic review of mass media 
campaigns to increase uptake in HIV testing found that these 
interventions can increase testing rates, although no studies 
included in the review were from LMIC.189 This review 
found one study conducted in a resource-limited setting – 
a retrospective cohort study in Kenya.190 Further research is 
needed on the efficacy of mass media campaigns and their 
potential to increase access and adherence.
Cost-effectiveness research is needed to evaluate the 
feasibility of implementing effective interventions in 
resource-limited settings and is just beginning to emerge. 
Overall, cost models have shown that high levels of adher-
ence are associated with overall lower total health care costs 
in the US191 and in South Africa.192 There is limited research 
available on the cost-effectiveness in LMIC of various HIV-
testing approaches,35,37,38 task-shifting to nurse-based care,67 
and home-based ART care.193 There is a need to expand cost 
research in terms of overall reductions in health care costs 
associated with improved access and adherence to ART and 
the cost-effectiveness of efficacious strategies. With these 
data, programs can reliably estimate overall cost savings 
projections for efforts to improve access and adherence. 
Still, cost factors related to the price of ART remain outside 
the control of local HIV programs. Global partners, phar-
maceutical companies, and national governments in LMIC 
need to continue to work together to create favorable global 
markets for ART whereby HIV programs in resource-limited 
settings gain increased access to the best available HIV 
medicines in line with WHO guidelines.194
Finally, new and creative directions in research are 
needed to address challenges in identifying effective strate-
gies to improve access and adherence to ART in LMIC. 
RCTs are commonly considered the gold standard, but 
as research on HIV interventions moves forward, it is 
important to balance the strengths and weaknesses of RCTs 
against those of well-designed observational studies. For 
public health and sociobehavioral interventions, there is a 
place for observational studies, and complete reliance on 
RCTs is not always good practice.195 The use of qualitative 
data alongside RCTs is still relatively uncommon and not 
without methodological issues,196 but may be positioned to 
evaluate complex and multicomponent interventions. Beyond 
the scope of studies assessing intervention effectiveness 
is operational and implementation research. Operational 
research, using systematic research techniques to improve 
program operations and decision-making197 will be a criti-
cal endeavor for health care systems in LMIC to strengthen 
health infrastructure, human resources and capacity for local 
program design and evaluation.198 Implementation research, 
investigating how health systems implement and deliver 
evidence-based interventions,199 will be critical to guide 
governments and policy makers in replicating, adapting, and 
scaling up interventions.
Conclusion
Individuals living with HIV encounter many barriers to 
access and adherence to treatment. This nonsystematic 
review revealed few effective evidence-based strategies 
to guide clinicians, public health practitioners, and other 
health care providers. These findings make a compel-
ling case for more data on improving delivery of ART in 
LMIC.
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